Dihexa

What Dihexa does

Dihexa is an experimental memory peptide studied in animals and lab cells, with no direct human study identified. A key paper was retracted and the original development paper has a notice of concern; long-term safety is unknown, including a theoretical concern about cancer growth.

• In animal studies it was explored as a memory drug; one mouse study reported benefit, but a key early paper was retracted. (animal)
• People report more creativity, focus, learning or energy, though these are personal impressions and one user felt nothing. (Reported by users)
• Some people report trying it after a concussion, but no trial has shown that taking it helps. (Reported by users)

Uses in the sources

• People report using it for learning, memory and creativity. These reports do not establish benefit. (Reported by users) (source)
• Some people self-experiment after concussion or cognitive symptoms. No trial has established benefit from directly taking dihexa. (Reported by users) (source)

Dihexa dosage

Typical reported dose: 10 mg under the tongue twice a week

• 10 mg twice weekly: 10 mg under the tongue twice weekly twice weekly, under the tongue. Reported by users, rare report. Studied in: Adults posting self-experiments online; identity and product content unverified. (source)
• Five daily doses, then weekly: 15 mg daily for 5 days, then 20 mg once weekly daily for 5 days, then once weekly, under the tongue. Reported by users, rare report. Studied in: Adults posting self-experiments online; identity and product content unverified. (source)
• 5-10 mg weekly report: 5-10 mg once weekly once weekly, by mouth. Reported by users, rare report. Studied in: Adults posting self-experiments online; identity and product content unverified. (source)
• 20 mg daily, planned breaks: 20 mg daily daily, by mouth. Reported by users, rare report. Studied in: Adults posting self-experiments online; identity and product content unverified. (source)
• 10 mg, then 5 mg: 10 mg every other day for 1 week, then reduced to 5 mg every other day initially; later frequency not restated, by mouth. Reported by users, rare report. Studied in: Adults posting self-experiments online; identity and product content unverified. (source)
• Skin application every 3-5 days: 15-30 mg in a DMSO preparation every 3-5 days every 3-5 days, skin patch. Reported by users, rare report. Studied in: Adults posting self-experiments online; identity and product content unverified. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix Dihexa

Comes as: Oral capsules or tablets reported online, Powder vials and oral/under-tongue solutions reported online, Transdermal DMSO mixtures reported online.

Mixed with: DMSO and mixed-solvent preparations appear in reports. No human-use diluent or recipe is established..

Common vial sizes: 10 mg. Common water amounts: mL.

• 10 mg is an observed vial size, not a measured market standard.
• Users report cloudy or poorly dissolved mixtures with bacteriostatic water. This is not a verified formulation.
• Do not infer sterility or suitability for injection from a clear solution or a chemical-purity result.

Before mixing: No validated human-product temperature or shelf life identified. Research-lab storage is not a product stability study.

After mixing: No validated storage temperature or expiry after mixing identified.

Dihexa side effects and risks

Reported side effects

• Changes in behavior or face recognition: One report described more rigid routines and worse face recognition; no incidence estimate., moderate. Stop and discuss new changes with a clinician. Other medicines confound the report. (source)
• Sleepiness or exhaustion: A commenter reported exhaustion about 2 hours after oral 8 mg and again after 4 mg., moderate. Avoid driving when sleepy; seek review of new or persistent symptoms. (source)
• Overfocus and emotional dulling: Reported with oral 50 mg plus stimulants; no causal attribution or rate is possible., moderate (source)
• Allergy or infection related to the product: General unapproved product risk, not a measured dihexa event rate., serious. Breathing problems or spreading injection-site infection need urgent care. (source)

Stop and get help if

• Trouble breathing, throat or tongue swelling, collapse or fainting after exposure.: Call emergency services now. These can be signs of anaphylaxis.
• A hot, painful, spreading red injection site, especially with fever or feeling very ill.: Seek urgent medical care. Confusion, fainting or fast breathing needs emergency care.

Who should avoid it

• pregnant: Precautionary block: no pregnancy safety data for directly taking dihexa.
• breastfeeding: Precautionary block: milk transfer and infant effects are unknown.
• tryingToConceive: Precautionary block: fertility and early-pregnancy safety are unknown.
• under18: Precautionary block: no pediatric dosing or developmental safety data.
• activeCancer: Proposed HGF/MET growth signaling raises a theoretical cancer-growth concern. No safe exposure is established.
• cancerHistory: Discuss prior cancer or unexplained new lumps with the treating clinician; the possible growth-signaling risk is unquantified.
• psychiatricCondition: Anecdotes include behavior changes. Existing psychiatric illness and psychoactive-drug combinations need review.
• kidneyDisease: No direct-dihexa human clearance data or kidney-dose adjustment is established.
• liverDisease: No direct dihexa human metabolism data or liver-dose adjustment is established.
• testedAthlete: Unapproved pharmacological substances are prohibited under the 2026 List; growth-factor rules may also apply.

Interactions

• Other nootropics and psychoactive drugs: No interaction studies establish safe combinations. Stimulant and nootropic stacks confound reports of mood, sleep and focus changes.

Product quality risks

• General peptide warnings describe wrong ingredients, wrong amounts and microbial or solvent contamination. No independent market survey of this compound was located.
• A purity percentage cannot establish dose, identity, sterility or clinical safety.
• Research-use labeling does not mean a product meets medicine quality standards.

What to expect

No human study giving dihexa directly was identified. Five animal and lab papers include one retracted paper; related fosgonimeton trials cannot establish dihexa's benefit or safety.

Key studies

• Original rat development study: Early animal findings carry a formal notice of concern. (source)
• HGF/MET mechanism paper, retracted: Retracted findings cannot establish the mechanism or a dose. (source)
• Alzheimer-like mouse study: A mouse study reported benefit, with an unresolved route error. (source)
• Negative Huntington-like rat study: No benefit was found in this Huntington-like rat model. (source)
• Working memory after repeated brain injury: A later rat experiment supports some MET-related effects. (source)

Dihexa FAQ

• Is Dihexa FDA-approved? No FDA-approved dihexa product or label located. No posted positive PCAC decision found; the planned review is not approval.
• How do people take it? Under the tongue, twice weekly. About 6 months. Source: reported by users, not an established dose.
• What's the difference between Dihexa and Semax? Dihexa: an experimental memory compound with disputed animal research and no established human dose. Semax: a Russian nasal peptide with limited human evidence for brain and nerve effects. Why people pair them: one poster planned Semax nasal spray while using dihexa. Concurrent use was not documented.
• Can I take it with Semax? One poster planned Semax nasal spray while using dihexa. Concurrent use was not documented. No human combination trial identified. This source describes a planned combination, not completed coadministration. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Rule-based classification of unapproved substances; neither is named. Growth-factor mimetics may fall under S2. Confirm with the anti-doping body.
• How long does a mixed vial last? No validated storage temperature or expiry after mixing identified.